Talphera Inc
R5XA
Company Profile
Business description
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Contact
1850 Gateway Drive
Suite 175
San MateoCA94404
USAT: +1 650 216-3500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
stocks
Bookworm: Is this the secret to exceptional long-term returns?
Acceptance may be an investor’s best friend.
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,953.10 | 18.80 | 0.21% |
| CAC 40 | 7,834.58 | 16.30 | 0.21% |
| DAX 40 | 24,217.50 | 78.43 | -0.32% |
| Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
| FTSE 100 | 9,120.31 | 18.06 | -0.20% |
| HKSE | 25,490.45 | 102.10 | 0.40% |
| NASDAQ | 21,108.32 | 50.36 | 0.24% |
| Nikkei 225 | 41,054.84 | 401.39 | -0.97% |
| NZX 50 Index | 12,895.76 | 42.30 | 0.33% |
| S&P 500 | 6,388.64 | 25.29 | 0.40% |
| S&P/ASX 200 | 8,689.50 | 22.60 | 0.26% |
| SSE Composite Index | 3,587.69 | 5.97 | -0.17% |